| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
16,907 |
8,611 |
$1.90M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
22,256 |
13,988 |
$871K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
10,703 |
7,005 |
$788K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
14,385 |
8,492 |
$454K |
| 0240U |
|
1,846 |
1,670 |
$212K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
8,341 |
6,992 |
$204K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
3,894 |
2,657 |
$178K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
220 |
162 |
$3K |
| 87420 |
|
61 |
54 |
$763.79 |